Evidence map›Paper›PMID 37795451›Full record

ArticleFrontiers in oncology2023

Insight of novel biomarkers for papillary thyroid carcinoma through multiomics.

Wei Liu, Junkan Zhu, Zhen Wu, Yongxiang Yin, Qiao Wu, Yiming Wu, Jiaojiao Zheng, Cong Wang, Hongyan Chen, Talal Jamil Qazi and 7 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.6field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. mRNA Isoforms and Variants in Health and Disease.International journal of molecular sciences · 2025
    Review
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 8 institutions in 2 countries.

Wei LiuDepartment of Surgery (Thyroid & Breast), Zhongshan Hospital, Fudan University, Shanghai, China.
Junkan ZhuDepartment of Surgery (Thyroid & Breast), Zhongshan Hospital, Fudan University, Shanghai, China.
Zhen WuState Key Laboratory of Genetic Engineering, School of Life Sciences, Fudan University, Shanghai, China.
Yongxiang YinDepartment of Pathology, Wuxi Maternal and Child Health Care Hospital, Womens Hospital of Jiangnan University, Jiangnan University, Jiangsu, China.
Qiao WuDepartment of Surgery (Thyroid & Breast), Zhongshan Hospital, Fudan University, Shanghai, China.
Yiming WuShanghai WeHealth BioMedical Technology Co., Ltd., Shanghai, China.
Jiaojiao ZhengDepartment of Surgery (Thyroid & Breast), Zhongshan Hospital, Fudan University, Shanghai, China.
Cong WangDepartment of Surgery (Thyroid & Breast), Zhongshan Hospital, Fudan University, Shanghai, China.
Hongyan ChenState Key Laboratory of Genetic Engineering, School of Life Sciences, Fudan University, Shanghai, China.
Talal Jamil QaziDepartment of Biomedical Engineering, Balochistan University of Engineering and Technology, Khuzdar, Pakistan.
Jun WuChinese Academy of Sciences Center for Excellence in Molecular Cell Science, Cell Bank, Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences, University of Chinese Academy of Sciences, Shanghai, China.
Yuqing ZhangChinese Academy of Sciences Center for Excellence in Molecular Cell Science, Cell Bank, Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences, University of Chinese Academy of Sciences, Shanghai, China.
Houbao LiuDepartment of General Surgery, Zhongshan Hospital, Fudan University, Shanghai, China.
Jingmin YangState Key Laboratory of Genetic Engineering, School of Life Sciences, Fudan University, Shanghai, China.
Daru LuState Key Laboratory of Genetic Engineering, School of Life Sciences, Fudan University, Shanghai, China.
Xumin ZhangState Key Laboratory of Genetic Engineering, School of Life Sciences, Fudan University, Shanghai, China.
Zhilong AiDepartment of Surgery (Thyroid & Breast), Zhongshan Hospital, Fudan University, Shanghai, China.
Fudan University · CNZhongshan Hospital · CNCenter for Excellence in Molecular Cell Science · CNBalochistan University of Engineering and Technology · PKHealth Biomed (China) · CNJiangnan University · CNSun Yat-sen University · CNThe First Affiliated Hospital, Sun Yat-sen University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: The overdiagnosing of papillary thyroid carcinoma (PTC) in China necessitates the development of an evidence-based diagnosis and prognosis strategy in line with precision medicine. A landscape of PTC in Chinese cohorts is needed to provide comprehensiveness. Methods: 6 paired PTC samples were employed for whole-exome sequencing, RNA sequencing, and data-dependent acquisition mass spectrum analysis. Weighted gene co-expression network analysis and protein-protein interactions networks were used to screen for hub genes. Moreover, we verified the hub genes' diagnostic and prognostic potential using online databases. Logistic regression was employed to construct a diagnostic model, and we evaluated its efficacy and specificity based on TCGA-THCA and GEO datasets. Results: The basic multiomics landscape of PTC among local patients were drawn. The similarities and differences were compared between the Chinese cohort and TCGA-THCA cohorts, including the identification of PNPLA5 as a driver gene in addition to BRAF mutation. Besides, we found 572 differentially expressed genes and 79 differentially expressed proteins. Through integrative analysis, we identified 17 hub genes for prognosis and diagnosis of PTC. Four of these genes, ABR, AHNAK2, GPX1, and TPO, were used to construct a diagnostic model with high accuracy, explicitly targeting PTC (AUC=0.969/0.959 in training/test sets). Discussion: Multiomics analysis of the Chinese cohort demonstrated significant distinctions compared to TCGA-THCA cohorts, highlighting the unique genetic characteristics of Chinese individuals with PTC. The novel biomarkers, holding potential for diagnosis and prognosis of PTC, were identified. Furthermore, these biomarkers provide a valuable tool for precise medicine, especially for immunotherapeutic or nanomedicine based cancer therapy.

Indexed as

biomarkersdiagnosislandscapemultiomicspapillary thyroid carcinomapredictionprognosis

Identifiers

PMID37795451
PMCPMC10546062
OpenAlexW4386856027

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.